Literature DB >> 27318146

Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease.

Rebecca F Rosen1, Yasushi Tomidokoro2, Aaron S Farberg3, Jeromy Dooyema3, Brian Ciliax4, Todd M Preuss5, Thomas A Neubert6, Jorge A Ghiso7, Harry LeVine8, Lary C Walker9.   

Abstract

The misfolding and accumulation of the protein fragment β-amyloid (Aβ) is an early and essential event in the pathogenesis of Alzheimer's disease (AD). Despite close biological similarities among primates, humans appear to be uniquely susceptible to the profound neurodegeneration and dementia that characterize AD, even though nonhuman primates deposit copious Aβ in senile plaques and cerebral amyloid-β angiopathy as they grow old. Because the amino acid sequence of Aβ is identical in all primates studied to date, we asked whether differences in the properties of aggregated Aβ might underlie the vulnerability of humans and the resistance of other primates to AD. In a comparison of aged squirrel monkeys (Saimiri sciureus) and humans with AD, immunochemical and mass spectrometric analyses indicate that the populations of Aβ fragments are largely similar in the 2 species. In addition, Aβ-rich brain extracts from the brains of aged squirrel monkeys and AD patients similarly seed the deposition of Aβ in a transgenic mouse model. However, the epitope exposure of aggregated Aβ differs in sodium dodecyl sulfate-stable oligomeric Aβ from the 2 species. In addition, the high-affinity binding of (3)H Pittsburgh Compound B to Aβ is significantly diminished in tissue extracts from squirrel monkeys compared with AD patients. These findings support the hypothesis that differences in the pathobiology of aggregated Aβ among primates are linked to post-translational attributes of the misfolded protein, such as molecular conformation and/or the involvement of species-specific cofactors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyloid; Cerebral amyloid angiopathy; Primate; Prion; Seeding; Senile plaques; Tauopathy

Mesh:

Substances:

Year:  2016        PMID: 27318146      PMCID: PMC4913040          DOI: 10.1016/j.neurobiolaging.2016.04.019

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  118 in total

Review 1.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

2.  Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB.

Authors:  K Serdons; T Verduyckt; D Vanderghinste; J Cleynhens; P Borghgraef; P Vermaelen; C Terwinghe; F Van Leuven; K Van Laere; H Kung; G Bormans; A Verbruggen
Journal:  Bioorg Med Chem Lett       Date:  2008-12-24       Impact factor: 2.823

3.  Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.

Authors:  Jun Maeda; Bin Ji; Toshiaki Irie; Takami Tomiyama; Masahiro Maruyama; Takashi Okauchi; Matthias Staufenbiel; Nobuhisa Iwata; Maiko Ono; Takaomi C Saido; Kazutoshi Suzuki; Hiroshi Mori; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2007-10-10       Impact factor: 6.167

4.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

5.  Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain.

Authors:  Asa Hatami; Ricardo Albay; Sanaz Monjazeb; Saskia Milton; Charles Glabe
Journal:  J Biol Chem       Date:  2014-10-03       Impact factor: 5.157

Review 6.  Preclinical Alzheimer disease-the challenges ahead.

Authors:  Reisa A Sperling; Jason Karlawish; Keith A Johnson
Journal:  Nat Rev Neurol       Date:  2012-11-27       Impact factor: 42.937

7.  Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

Authors:  Justin M Nussbaum; Stephan Schilling; Holger Cynis; Antonia Silva; Eric Swanson; Tanaporn Wangsanut; Kaycie Tayler; Brian Wiltgen; Asa Hatami; Raik Rönicke; Klaus Reymann; Birgit Hutter-Paier; Anca Alexandru; Wolfgang Jagla; Sigrid Graubner; Charles G Glabe; Hans-Ulrich Demuth; George S Bloom
Journal:  Nature       Date:  2012-05-02       Impact factor: 49.962

Review 8.  Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease.

Authors:  Sergio T Ferreira; Mychael V Lourenco; Mauricio M Oliveira; Fernanda G De Felice
Journal:  Front Cell Neurosci       Date:  2015-05-26       Impact factor: 5.505

9.  Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) pores.

Authors:  Alan L Gillman; Hyunbum Jang; Joon Lee; Srinivasan Ramachandran; Bruce L Kagan; Ruth Nussinov; Fernando Teran Arce
Journal:  J Phys Chem B       Date:  2014-06-24       Impact factor: 2.991

Review 10.  Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.

Authors:  Lidia Bakota; Roland Brandt
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

View more
  18 in total

1.  Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.

Authors:  Erwin Cabrera; Paul Mathews; Emiliya Mezhericher; Thomas G Beach; Jingjing Deng; Thomas A Neubert; Agueda Rostagno; Jorge Ghiso
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-13       Impact factor: 5.187

2.  Ultrastructural analysis of parvalbumin synapses in human dorsolateral prefrontal cortex.

Authors:  Jill R Glausier; Rosalinda C Roberts; David A Lewis
Journal:  J Comp Neurol       Date:  2017-03-26       Impact factor: 3.215

Review 3.  The Exceptional Vulnerability of Humans to Alzheimer's Disease.

Authors:  Lary C Walker; Mathias Jucker
Journal:  Trends Mol Med       Date:  2017-05-05       Impact factor: 11.951

4.  Aβ Plaques.

Authors:  Lary C Walker
Journal:  Free Neuropathol       Date:  2020-10-30

Review 5.  Alzheimer's disease: experimental models and reality.

Authors:  Eleanor Drummond; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2016-12-26       Impact factor: 17.088

6.  Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.

Authors:  Ian Diner; Jeromy Dooyema; Marla Gearing; Lary C Walker; Nicholas T Seyfried
Journal:  Bioconjug Chem       Date:  2017-09-22       Impact factor: 4.774

7.  Age-related changes in chimpanzee (Pan troglodytes) cognition: Cross-sectional and longitudinal analyses.

Authors:  William D Hopkins; Mary C Mareno; Sarah J Neal Webb; Steven J Schapiro; Mary A Raghanti; Chet C Sherwood
Journal:  Am J Primatol       Date:  2020-11-10       Impact factor: 2.371

8.  Quantification of neurons in the hippocampal formation of chimpanzees: comparison to rhesus monkeys and humans.

Authors:  Christina N Rogers Flattery; Rebecca F Rosen; Aaron S Farberg; Jeromy M Dooyema; Patrick R Hof; Chet C Sherwood; Lary C Walker; Todd M Preuss
Journal:  Brain Struct Funct       Date:  2020-09-09       Impact factor: 3.270

Review 9.  The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease.

Authors:  Heather H C Lau; Martin Ingelsson; Joel C Watts
Journal:  Acta Neuropathol       Date:  2020-08-02       Impact factor: 17.088

Review 10.  Comparative neuropathology in aging primates: A perspective.

Authors:  Carmen Freire-Cobo; Melissa K Edler; Merina Varghese; Emily Munger; Jessie Laffey; Sophia Raia; Selena S In; Bridget Wicinski; Maria Medalla; Sylvia E Perez; Elliott J Mufson; Joseph M Erwin; Elaine E Guevara; Chet C Sherwood; Jennifer I Luebke; Agnès Lacreuse; Mary A Raghanti; Patrick R Hof
Journal:  Am J Primatol       Date:  2021-07-13       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.